Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Diego
This is a placebo-controlled randomized controlled trial enrolling dyads of birthing people and their newborn infants. We will explore if the type and timing of initiation of pills is acceptable to the user with minimal side effects, impacts the supply or composition of breastmilk, and/or affects infant growth.
Birthing people will be randomly assigned to 1 of 3 groups and will be blinded to group assignment:
1. immediate initiation of drospirenone-containing progestin-only pills (d-POPs),
2. immediate initiation of norethindrone-containing progestin-only pills (n-POPs)
3. immediate initiation of a placebo pill for one month followed by d-POPs.
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
18 years of age and older
Desires to use POPs for 3 months
Speak English or Spanish
Had a vaginal or cesarean delivery of a singleton full term (≥37 weeks) infant less than 168 hours prior
Intends to breastfeed exclusively for 6 months
You may not be if
Desire another pregnancy in less than 6 months
Do not intend to exclusively breastfeed
Do not have access to a telephone
Have any medical contraindication to POPs
Have any contraindication to breastfeeding, including maternal illegal drug use, history of augmentation or reduction, infant with major congenital anomaly